CS Diagnostics Corp. is a medical distribution company that provides the advancing patient care through innovative solutions. The firm is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. The company is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. The company includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.
How did CSDX's recent EPS compare to expectations?
The most recent EPS for CS Diagnostics Corp is $, expectations of $.
How did CS Diagnostics Corp CSDX's revenue perform in the last quarter?
CS Diagnostics Corp revenue for the last quarter is $
What is the revenue estimate for CS Diagnostics Corp?
According to of Wall street analyst, the revenue estimate of CS Diagnostics Corp range from $ to $
What's the earning quality score for CS Diagnostics Corp?
CS Diagnostics Corp has a earning quality score of B/42.517868. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does CS Diagnostics Corp report earnings?
CS Diagnostics Corp next earnings report is expected in
What are CS Diagnostics Corp's expected earnings?
CS Diagnostics Corp expected earnings is $, according to wall-street analysts.
Did CS Diagnostics Corp beat earnings expectations?
CS Diagnostics Corp recent earnings of $ expectations.